{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T18:49:16Z","timestamp":1775155756153,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum D\u00fcsseldorf. Anstalt \u00f6ffentlichen Rechts"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    As median age of patients with acute myeloid leukemia is 72 years, older patients continue to be a vulnerable cohort representing significant challenges in clinical practice. Patient-specific comorbidities as well as leukemia-specific unfavorable molecular- and cytogenetics confer even poorer outcomes. Treatment of AML therefore needs to be less toxic to prevent harm while lowering or eradicating leukemic burden to prolong survival. In this retrospective analysis we included 365 older AML patients from the D\u00fcsseldorf registry who were diagnosed and treated in our department of hematology over a period of 31 years. Most patients were treated with HMA (37.3%) followed by 35.3% of patients who received either low dose chemotherapy or BSC. 9% of patients were treated with induction chemotherapy while 8.5% of patients received a combination of HMA with venetoclax. 4.1% of patients underwent allografting. At the time of last follow up, 35 patients (9.6%) were still alive. Of those patients who were treated with induction chemotherapy or HMA\u2009+\u2009venetoclax, 18.2% and 29.0% were still alive, whereas 60% of the patients who underwent allogeneic stem cell transplantation were still alive (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Median overall survival of the entire patient population was 6 months. Longest survival was observed in patients who underwent aHSCT with an unreached median overall survival followed by patients who were treated with induction chemotherapy (21 months) or HMA plus venetoclax (11 months). The implementation of HMA\u2009+\u2009venetoclax and increasing numbers of aHSCT improved prognosis and survival even in older AML patients.\n                  <\/jats:p>","DOI":"10.1007\/s00277-025-06196-2","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T19:03:01Z","timestamp":1736535781000},"page":"231-239","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Outcomes in patients with acute myeloid leukemia older than 70 years within the last 30 years, a single center experience"],"prefix":"10.1007","volume":"104","author":[{"given":"Felicitas","family":"Schulz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Roggenbuck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"K\u00fcndgen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annika","family":"Kasprzak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin","family":"Nachtkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sascha","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Kobbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Germing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,11]]},"reference":[{"key":"6196_CR1","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s00761-017-0249-z","volume":"23","author":"K Kraywinkel","year":"2017","unstructured":"Kraywinkel K, Spix C (2017) Epidemiology of acute leukemia in Germany. Onkologe 23:499\u2013503","journal-title":"Onkologe"},{"issue":"7","key":"6196_CR2","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and Histiocytic\/Dendritic neoplasms. Leukemia 36(7):1703\u20131719. https:\/\/doi.org\/10.1038\/s41375-022-01613-1","journal-title":"Leukemia"},{"key":"6196_CR3","doi-asserted-by":"publisher","unstructured":"Daniel A, Arber A, Orazi RP, Hasserjian MJ, Borowitz KR, Calvo H-M, Kvasnicka SA, Wang A, Bagg T, Barbui S, Branford CE, Bueso-Ramos JE, Cortes PD, Cin, Courtney D, DiNardo EJ, Duncavage BL, Ebert, Elihu H, Estey F, Facchetti K, Foucar N, Gangat U, Gianelli LA, Godley S, Hobbs R, Hoffman EJ, Jabbour J-J, Kiladjian RA, Larson, Michelle M, Le Beau ML-C, Loh B, L\u00f6wenberg E, Macintyre L, Malcovati CG, Mullighan OM, Odenike S, Ogawa A, Orfao E, Papaemmanuil F, Passamonti K, Porkka C-H, Pui JP Radich, Andreas Reiter, Maria Rozman, Martina Rudelius, Savona MR, Schiffer CA, Annette Schmitt-Graeff, Akiko Shimamura, Jorge Sierra, Stock WA, Stone RM, Vannucchi MS, Vyas P, Wei AH (2022) Olga K. Weinberg, Agnieszka Wierzbowska, Mario Cazzola, Hartmut D\u00f6hner, Ayalew Tefferi; International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood; 140 (11): 1200\u20131228. https:\/\/doi.org\/10.1182\/blood.2022015850","DOI":"10.1182\/blood.2022015850"},{"issue":"20","key":"6196_CR4","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"A Daniel","year":"2016","unstructured":"Daniel A, Arber A, Orazi R, Hasserjian J\u00fcrgen, Thiele MJ, Borowitz, Michelle M, Le Beau CD, Bloomfield M, Cazzola JW, Vardiman (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"issue":"9","key":"6196_CR5","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","volume":"107","author":"FR Appelbaum","year":"2006","unstructured":"Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, Anderson JE, Petersdorf SH (2006) Age and acute myeloid leukemia. Blood 107(9):3481\u20133485. https:\/\/doi.org\/10.1182\/blood-2005-09-3724","journal-title":"Blood"},{"issue":"5","key":"6196_CR6","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/cncr.21723","volume":"106","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, O\u2019brien S, Cortes J, Giles F, Faderl S, Jabbour E, Garcia-Manero G, Wierda W, Pierce S, Shan J, Estey E (2006) Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 106(5):1090\u20131098. https:\/\/doi.org\/10.1002\/cncr.21723","journal-title":"Cancer"},{"issue":"7","key":"6196_CR7","doi-asserted-by":"publisher","first-page":"926","DOI":"10.6004\/jnccn.2017.0116","volume":"15","author":"MR O\u2019Donnell","year":"2017","unstructured":"O\u2019Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Bhatt V, Bixby D, Blum W, Coutre SE, De Lima M, Fathi AT, Fiorella M, Foran JM, Gore SD, Hall AC, Kropf P, Lancet J, Maness LJ, Marcucci G, Martin MG, Moore JO, Olin R, Peker D, Pollyea DA, Pratz K, Ravandi F, Shami PJ, Stone RM, Strickland SA, Wang ES, Wieduwilt M, Gregory K, Ogba N (2017) Acute myeloid leukemia, Version 3.2017, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw 15(7):926\u2013957. https:\/\/doi.org\/10.6004\/jnccn.2017.0116","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"6196_CR8","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/j.1365-2141.2010.08470.x","volume":"152","author":"DA Pollyea","year":"2011","unstructured":"Pollyea DA, Kohrt HE, Medeiros BC (2011) Acute myeloid leukaemia in the elderly: a review. Br J Haematol 152(5):524\u2013542. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08470.x","journal-title":"Br J Haematol"},{"issue":"4","key":"6196_CR9","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1053\/j.seminoncol.2008.04.013","volume":"35","author":"H Dombret","year":"2008","unstructured":"Dombret H, Raffoux E, Gardin C (2008) Acute myeloid leukemia in the elderly. Semin Oncol 35(4):430\u2013438. https:\/\/doi.org\/10.1053\/j.seminoncol.2008.04.013","journal-title":"Semin Oncol"},{"key":"6196_CR10","doi-asserted-by":"publisher","unstructured":"D\u00f6hner H, Andrew H, Wei FR, Appelbaum C, Craddock CD, DiNardo, Herv\u00e9 Dombret BL, Ebert P, Fenaux LA, Godley RP, Hasserjian RA, Larson RL, Levine J, Sierra EM, Stein MS, Tallman (2022) Hwei-Fang Tien, Jianxiang Wang, Agnieszka Wierzbowska, Bob L\u00f6wenberg; Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood; 140 (12): 1345\u20131377. https:\/\/doi.org\/10.1182\/blood.2022016867","DOI":"10.1182\/blood.2022016867"},{"issue":"2","key":"6196_CR11","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","volume":"19","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, Arellano M, Frattini MG, Kantarjian H, Popovic R, Chyla B, Xu T, Dunbar M, Agarwal SK, Humerickhouse R, Mabry M, Potluri J, Konopleva M, Pollyea DA (2018) Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol 19(2):216\u2013228. https:\/\/doi.org\/10.1016\/S1470-2045(18)30010-X","journal-title":"Lancet Oncol"},{"issue":"7","key":"6196_CR12","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, D\u00f6hner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, H\u00e1jek R, Porkka K, Ill\u00e9s \u00c1, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW (2020) Azacitidine and Venetoclax in previously untreated Acute Myeloid Leukemia. N Engl J Med 383(7):617\u2013629. https:\/\/doi.org\/10.1056\/NEJMoa2012971","journal-title":"N Engl J Med"},{"issue":"9","key":"6196_CR13","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","volume":"15","author":"RK Hills","year":"2014","unstructured":"Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, Estey EH, Dombret H, Chevret S, Ifrah N, Cahn JY, R\u00e9cher C, Chilton L, Moorman AV, Burnett AK (2014) Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol 15(9):986\u2013996. https:\/\/doi.org\/10.1016\/S1470-2045(14)70281-5","journal-title":"Lancet Oncol"},{"issue":"1","key":"6196_CR14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3324\/haematol.2018.188888","volume":"104","author":"J Lambert","year":"2019","unstructured":"Lambert J, Pautas C, Terr\u00e9 C, Raffoux E, Turlure P, Caillot D, Legrand O, Thomas X, Gardin C, Gogat-Marchant K, Rubin SD, Benner RJ, Bousset P, Preudhomme C, Chevret S, Dombret H, Castaigne S (2019) Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica 104(1):113\u2013119. https:\/\/doi.org\/10.3324\/haematol.2018.188888","journal-title":"Haematologica"},{"issue":"5","key":"6196_CR15","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, D\u00f6hner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, D\u00f6hner H (2017) Midostaurin plus chemotherapy for Acute myeloid leukemia with a FLT3 mutation. N Engl J Med 377(5):454\u2013464. https:\/\/doi.org\/10.1056\/NEJMoa1614359","journal-title":"N Engl J Med"},{"issue":"8","key":"6196_CR16","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S1470-2045(17)30416-3","volume":"18","author":"AE Perl","year":"2017","unstructured":"Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, Claxton D, Erba HP, Gill S, Goldberg S, Jurcic JG, Larson RA, Liu C, Ritchie E, Schiller G, Spira AI, Strickland SA, Tibes R, Ustun C, Wang ES, Stuart R, R\u00f6llig C, Neubauer A, Martinelli G, Bahceci E, Levis M (2017) Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1\u20132 study. Lancet Oncol 18(8):1061\u20131075. https:\/\/doi.org\/10.1016\/S1470-2045(17)30416-3","journal-title":"Lancet Oncol"},{"issue":"6","key":"6196_CR17","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","volume":"130","author":"EM Stein","year":"2017","unstructured":"Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, Stone RM, DeAngelo DJ, Levine RL, Flinn IW, Kantarjian HM, Collins R, Patel MR, Frankel AE, Stein A, Sekeres MA, Swords RT, Medeiros BC, Willekens C, Vyas P, Tosolini A, Xu Q, Knight RD, Yen KE, Agresta S, de Botton S, Tallman MS (2017) Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 130(6):722\u2013731. https:\/\/doi.org\/10.1182\/blood-2017-04-779405","journal-title":"Blood"},{"issue":"1","key":"6196_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1200\/JCO.20.01632","volume":"39","author":"CD DiNardo","year":"2021","unstructured":"DiNardo CD, Stein AS, Stein EM, Fathi AT, Frankfurt O, Schuh AC, D\u00f6hner H, Martinelli G, Patel PA, Raffoux E, Tan P, Zeidan AM, de Botton S, Kantarjian HM, Stone RM, Frattini MG, Lersch F, Gong J, Gianolio DA, Zhang V, Franovic A, Fan B, Goldwasser M, Daigle S, Choe S, Wu B, Winkler T, Vyas P (2021) Mutant isocitrate dehydrogenase 1 inhibitor Ivosidenib in Combination with azacitidine for newly diagnosed Acute myeloid leukemia. J Clin Oncol 39(1):57\u201365. https:\/\/doi.org\/10.1200\/JCO.20.01632","journal-title":"J Clin Oncol"},{"issue":"12","key":"6196_CR19","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele G, R\u00f6llig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, L\u00f6wenberg B (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u20131377. https:\/\/doi.org\/10.1182\/blood.2022016867","journal-title":"Blood"},{"key":"6196_CR20","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2307\/2281868","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457\u2013481. https:\/\/doi.org\/10.2307\/2281868","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"6196_CR21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.cger.2015.08.010","volume":"32","author":"HD Klepin","year":"2016","unstructured":"Klepin HD (2016) Myelodysplastic syndromes and Acute Myeloid Leukemia in the Elderly. Clin Geriatr Med 32(1):155\u2013173. https:\/\/doi.org\/10.1016\/j.cger.2015.08.010","journal-title":"Clin Geriatr Med"},{"issue":"15","key":"6196_CR22","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1182\/bloodadvances.2020001920","volume":"4","author":"MA Sekeres","year":"2020","unstructured":"Sekeres MA, Guyatt G, Abel G, Alibhai S, Altman JK, Buckstein R, Choe H, Desai P, Erba H, Hourigan CS, LeBlanc TW, Litzow M, MacEachern J, Michaelis LC, Mukherjee S, O\u2019Dwyer K, Rosko A, Stone R, Agarwal A, Colunga-Lozano LE, Chang Y, Hao Q, Brignardello-Petersen R (2020) American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. Blood Adv 4(15):3528\u20133549. https:\/\/doi.org\/10.1182\/bloodadvances.2020001920","journal-title":"Blood Adv"},{"key":"6196_CR23","unstructured":"PDF Version - SEER Cancer Statistics Review (CSR) (2016) 1975\u2013 SEER Accessed January 18, 2020. https:\/\/seer.cancer.gov\/csr\/1975_2016\/sections.html"},{"issue":"18","key":"6196_CR24","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","volume":"113","author":"G Juliusson","year":"2009","unstructured":"Juliusson G, Antunovic P, Derolf A et al (2009) Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 113(18):4179\u20134187. https:\/\/doi.org\/10.1182\/blood-2008-07-172007","journal-title":"Blood"},{"issue":"9","key":"6196_CR25","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1200\/JCO.1989.7.9.1268","volume":"7","author":"B L\u00f6wenberg","year":"1989","unstructured":"L\u00f6wenberg B, Zittoun R, Kerkhofs H et al (1989) On the value of intensive remission-induction chemotherapy in elderly patients of 65\u2009+\u2009years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol off J Am Soc Clin Oncol 7(9):1268\u20131274. https:\/\/doi.org\/10.1200\/JCO.1989.7.9.1268","journal-title":"J Clin Oncol off J Am Soc Clin Oncol"},{"issue":"1","key":"6196_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1200\/JCO.2007.15.4245","volume":"27","author":"T B\u00fcchner","year":"2009","unstructured":"B\u00fcchner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, M\u00fcller-Tidow C, Braess J, Spiekermann K, Kienast J, Staib P, Gr\u00fcneisen A, Kern W, Reichle A, Maschmeyer G, Aul C, Lengfelder E, Sauerland MC, Heinecke A, W\u00f6rmann B, Hiddemann W (2009) Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 27(1):61\u201369. https:\/\/doi.org\/10.1200\/JCO.2007.15.4245","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"6196_CR27","doi-asserted-by":"publisher","first-page":"8957","DOI":"10.4081\/hr.2020.8957","volume":"12","author":"T Haferlach","year":"2020","unstructured":"Haferlach T (2020) Advancing leukemia diagnostics: role of Next Generation sequencing (NGS) in acute myeloid leukemia. Hematol Rep 12(Suppl 1):8957. https:\/\/doi.org\/10.4081\/hr.2020.8957","journal-title":"Hematol Rep"},{"issue":"4","key":"6196_CR28","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/s41375-021-01425-9","volume":"36","author":"C R\u00e9cher","year":"2022","unstructured":"R\u00e9cher C, R\u00f6llig C, B\u00e9rard E, Bertoli S, Dumas PY, Tavitian S, Kramer M, Serve H, Bornh\u00e4user M, Platzbecker U, M\u00fcller-Tidow C, Baldus CD, Mart\u00ednez-Cuadr\u00f3n D, Serrano J, Mart\u00ednez-S\u00e1nchez P, Arbol\u00ed ER, Gil C, Bergua J, Bernal T, de la Fuente Burguera A, Delabesse E, Bidet A, Pigneux A, Montesinos P (2022) Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries. Leukemia 36(4):913\u2013922. https:\/\/doi.org\/10.1038\/s41375-021-01425-9","journal-title":"Leukemia"},{"issue":"10","key":"6196_CR29","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1182\/bloodadvances.2020001779","volume":"4","author":"AM Zeidan","year":"2020","unstructured":"Zeidan AM, Wang R, Wang X, Shallis RM, Podoltsev NA, Bewersdorf JP, Huntington SF, Neparidze N, Giri S, Gore SD, Davidoff AJ, Ma X (2020) Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. Blood Adv 4(10):2192\u20132201. https:\/\/doi.org\/10.1182\/bloodadvances.2020001779","journal-title":"Blood Adv"},{"issue":"1","key":"6196_CR30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, Wei AH, Kantarjian HM, Xu T, Hong WJ, Chyla B, Potluri J, Pollyea DA, Letai A (2019) Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133(1):7\u201317. https:\/\/doi.org\/10.1182\/blood-2018-08-868752","journal-title":"Blood"},{"issue":"7","key":"6196_CR31","doi-asserted-by":"publisher","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","volume":"8","author":"JE Lancet","year":"2021","unstructured":"Lancet JE, Uy GL, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Faderl S, Cortes JE (2021) CPX-351 versus 7\u2009+\u20093 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol 8(7):e481\u2013e491. https:\/\/doi.org\/10.1016\/S2352-3026(21)00134-4","journal-title":"Lancet Haematol"},{"issue":"3","key":"6196_CR32","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/ajh.26061","volume":"96","author":"A Maiti","year":"2021","unstructured":"Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY (2021) Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: a propensity score matched analysis stratified by risk of treatment-related mortality. Am J Hematol 96(3):282\u2013291. https:\/\/doi.org\/10.1002\/ajh.26061","journal-title":"Am J Hematol"},{"issue":"13","key":"6196_CR33","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1182\/bloodadvances.2022007265","volume":"6","author":"AH Matthews","year":"2022","unstructured":"Matthews AH, Perl AE, Luger SM, Loren AW, Gill SI, Porter DL, Babushok DV, Maillard IP, Carroll MP, Frey NV, Hexner EO, Martin ME, McCurdy SR, Stadtmauer EA, Paralkar VR, Bruno XJ, Hwang WT, Margolis D, Pratz KW (2022) Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia. Blood Adv 6(13):3997\u20134005. https:\/\/doi.org\/10.1182\/bloodadvances.2022007265","journal-title":"Blood Adv"},{"issue":"9","key":"6196_CR34","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1182\/blood-2017-03-772368","volume":"130","author":"L Muffly","year":"2017","unstructured":"Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, Aljurf M, Ballen KK, Bajel A, Baron F, Battiwalla M, Beitinjaneh A, Cahn JY, Carabasi M, Chen YB, Chhabra S, Ciurea S, Copelan E, D\u2019Souza A, Edwards J, Foran J, Freytes CO, Fung HC, Gale RP, Giralt S, Hashmi SK, Hildebrandt GC, Ho V, Jakubowski A, Lazarus H, Luskin MR, Martino R, Maziarz R, McCarthy P, Nishihori T, Olin R, Olsson RF, Pawarode A, Peres E, Rezvani AR, Rizzieri D, Savani BN, Schouten HC, Sabloff M, Seftel M, Seo S, Sorror ML, Szer J, Wirk BM, Wood WA, Artz A (2017) Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood 130(9):1156\u20131164. https:\/\/doi.org\/10.1182\/blood-2017-03-772368","journal-title":"Blood"},{"issue":"16","key":"6196_CR35","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","volume":"386","author":"P Montesinos","year":"2022","unstructured":"Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Bertani G, Heuser M, Calado RT, Schuh AC, Yeh SP, Daigle SR, Hui J, Pandya SS, Gianolio DA, de Botton S, D\u00f6hner H (2022) Ivosidenib and Azacitidine in IDH1-Mutated Acute myeloid leukemia. N Engl J Med 386(16):1519\u20131531. https:\/\/doi.org\/10.1056\/NEJMoa2117344","journal-title":"N Engl J Med"},{"key":"6196_CR36","doi-asserted-by":"crossref","unstructured":"Roboz, G. J., DiNardo, C. D., Stein, E. M., de Botton, S., Mims, A. S., Prince, G.T.,\u2026 Stone, R. M. (2020). Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.Blood, The Journal of the American Society of Hematology, 135(7), 463\u2013471","DOI":"10.1182\/blood.2019002140"},{"issue":"18","key":"6196_CR37","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, Montesinos P, Baer MR, Larson RA, Ustun C, Fabbiano F, Erba HP, Di Stasi A, Stuart R, Olin R, Kasner M, Ciceri F, Chou WC, Podoltsev N, Recher C, Yokoyama H, Hosono N, Yoon SS, Lee JH, Pardee T, Fathi AT, Liu C, Hasabou N, Liu X, Bahceci E, Levis MJ (2019) Gilteritinib or Chemotherapy for relapsed or refractory FLT3-Mutated AML. N Engl J Med 381(18):1728\u20131740. https:\/\/doi.org\/10.1056\/NEJMoa1902688","journal-title":"N Engl J Med"},{"key":"6196_CR38","doi-asserted-by":"crossref","unstructured":"Issa, G. C., Aldoss, I., DiPersio, J. F., Cuglievan, B., Stone, R. M., Arellano, M.L.,\u2026 Stein, E. (2022). The menin inhibitor SNDX-5613 (revumenib) leads to durable responses in patients (Pts) with KMT2A-rearranged or NPM1 mutant AML: updated results of a phase (Ph) 1 study.Blood, 140(Supplement 1), 150\u2013152","DOI":"10.1182\/blood-2022-164849"},{"issue":"2","key":"6196_CR39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41408-021-00410-w","volume":"11","author":"A Maiti","year":"2021","unstructured":"Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Loghavi S, Montalbano KS, Pierce S, Wierda WG, Kantarjian HM, Konopleva MY (2021) Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J 11(2):25. https:\/\/doi.org\/10.1038\/s41408-021-00410-w","journal-title":"Blood Cancer J"},{"key":"6196_CR40","doi-asserted-by":"crossref","unstructured":"Lachowiez, C. A., Borthakur, G., Loghavi, S., Zeng, Z., Kadia, T. M., Masarova, L.,\u2026 Dinardo, C. D. (2021). A phase Ib\/II study of ivosidenib with venetoclax+\/-azacitidine in IDH1-mutated myeloid malignancies.","DOI":"10.1200\/JCO.2021.39.15_suppl.7012"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06196-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06196-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06196-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T01:04:22Z","timestamp":1751331862000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06196-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["6196"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06196-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5144621\/v1","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"24 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Heinrich-Heine University in Duesseldorf.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all subjects in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"F.N.: Stock in Gilead and 270Bio, equity in ORNA, MPM entrepreneur partner. G.K.: Advisory Role, Speaker Honoraria and\/or travel support: MSD, Pfizer, Amgen, Novartis, Gilead, BMS-Celgene, Abbvie, Medac, Biotest, Takeda, Eurocept. Financing of scientific research: BMS-Celgene, Amgen, Abbvie, Eurocept, Medac. U.G.: Institutional research support: BMS, Abbvie, Jazz. Speaker honoraria: BMS, Jansen.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}